Maxim Group Thinks Biolase’s Stock is Going to Recover
January 11 2022 - 03:35PM
TipRanks
Maxim Group analyst Anthony Vendetti reiterated a Buy rating on
Biolase (BIOL – Research Report) yesterday and set a price target
of $2.00. The company's shares closed last Tuesday at $0.41, close
to its 52-week low of $0.27. According to TipRanks.com, Vendetti is
a 4-star analyst with an average return of 8.1% and a 38.2% success
rate. Vendetti covers the Healthcare sector, focusing on stocks
such as ReShape Lifesciences, Milestone Scientific, and Dermata
Therapeutics. Biolase has an analyst consensus of Moderate Buy,
with a price target consensus of $2.00, a 412.8% upside from
current levels.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-biolases-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Apr 2022 to May 2022
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From May 2021 to May 2022